Current approaches to the use of generic antiepileptic drugs

Epilepsy and Behavior

Volumn 11, Issue 1, 2007, Pages 46-52

  Kramer G ^a   Biraben, A ^b   Carreno, M ^c   Guekht, A ^d   de Haan, G J ^e   Jedrzejczak, J ^f   Josephs, D ^g   van Rijckevorsel, K ^h   Zaccara, G ⁱ  

^a SWISS EPILEPSY CENTER   (Switzerland)

^b PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^c HOSPITAL CLÍNIC   (Spain)

^d PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^e STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

^f MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

^g Joint Epilepsy Council of the UK and Ireland   (United Kingdom)

^h CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

ⁱ SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

Author keywords

Adherence; Bioequivalence; Cost; Epilepsy; Generic drugs; Seizure control

Indexed keywords

ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; CARBAMAZEPINE; ETIRACETAM; GENERIC DRUG; LAMOTRIGINE; PHENYTOIN; PREGABALIN; VALPROIC ACID;

BIOEQUIVALENCE; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE CONTROL; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG EXPOSURE; DRUG FORMULATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRUG USE; EPILEPSY; HEALTH CARE POLICY; HUMAN; MEDICAL DECISION MAKING; PATIENT COMPLIANCE; PATIENT INFORMATION; PATIENT RIGHT; PHARMACEUTICAL CARE; PHARMACIST; PRACTICE GUIDELINE; PRESCRIPTION; REVIEW; RISK BENEFIT ANALYSIS; SINGLE DRUG DOSE; STEVENS JOHNSON SYNDROME; UNSPECIFIED SIDE EFFECT;

ANTICONVULSANTS; DRUGS, GENERIC; EPILEPSY; HEALTH POLICY; HUMANS; PATIENT EDUCATION; PRESCRIPTIONS, DRUG; THERAPEUTIC EQUIVALENCY; UNITED STATES;

EID: 34447632809     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2007.03.014     Document Type: Review

References (35)

1. Crawford P., Feely M., Guberman A., and Kramer G. Are there potential problems with generic substitution of antiepileptic drugs? A review of issues. Seizure 15 (2006) 165-176
2. Crawford P., Hall W.W., Chappell B., Collings J., and Stewart A. Generic prescribing for epilepsy: is it safe?. Seizure 5 (1996) 1-5
3. Dutch Society of Child Neurology. Statement of Dutch Society of Child Neurology. 2005.
4. Dutch WINap. Dutch WINap Report about generic substitution, ; 2006 [accessed 09.03.07].
5. Krämer G., Dennig D., Schmidt D., et al. for the Ad Hoc Kommission der Deutschen Gesellschaft für Epileptologie. Generika in der Epilepsietherapie: was ist zu beacthen?. Akt Neurol 32 (2005) 275-278
6. Majkowski J., Lason W., Daniel W., et al. Brand-name and generic drugs in the treatment of epilepsy: biopharmaceutical, pharmacological, clinical and economic problems. Epileptologia 12 (2004) 365-389
7. NICE. The clinical effectiveness and cost effectiveness of newer drugs for epilepsy in children, ; 2004 [accessed 09.03.07].
8. Perucca E., Albani F., Capovilla G., Bernardina B.D., Michelucci R., and Zaccara G. Recommendations of the Italian League Against Epilepsy working group on generic products of antiepileptic drugs. Epilepsia 47 Suppl. 5 (2006) 16-20
9. Swedish Medical Product Agency (MPA). Swedish Medical Product Agency Statement. 2002.
10. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: generic substitution for antiepileptic medication. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 1990;40:1641-3.
11. NICE. The clinical effectiveness and cost effectiveness of newer drugs for epilepsy in adults, ; 2004 [accessed 09.03.07].
12. Scottish Intercollegiate Guidelines Network. Diagnosis and management of epilepsy in adults: a national clinical guideline, ; 2005 [accessed 09.03.07].
13. Epilepsy Foundation. Generic medications and epilepsy, ; 2006 [accessed 09.03.07].
14. American Academy of Neurology. Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy, ; 2006 [accessed 09.03.07].
15. Gonzalez de Dios J., Ochoa-Sangrador C., and Sempere A.P. Generic drugs in the treatment of epilepsy. Rev Neurol 41 (2005) 676-683
16. Krämer G., Schneble H., and Wolf P. for the Ad Hoc Kommission der Deutschen Sektion der Internationalen Liga gegen Epilepsie. Risiken der neuen Aut-idem-Regelung für die Behandlung mit Antiepileptika. Akt Neurol 29 (2002) 115-122
17. Krämer G., Steinhoff B., Feucht M., Pfaffin M., and May T. Generic preparations of antiepileptic drugs: experiences in Germany, Austria and Switzerland. Epilepsia 48 (2007) 609-611
18. Argumosa A., and Herranz J.L. The clinical and economic impact of generic drugs in the treatment of epilepsy. Rev Neurol 41 (2005) 45-49
19. Wilner A.N. Therapeutic equivalency of generic antiepileptic drugs: results of a survey. Epilepsy Behav 5 (2004) 995-998
20. Rosenbaum D.H., Rowan A.J., Tuchman L., and French J.A. Comparative bioavailability of a generic phenytoin and Dilantin. Epilepsia 35 (1994) 656-660
21. Meredith P. Bioequivalence and other unresolved issues in generic drug substitution. Clin Ther 25 (2003) 2875-2890
22. Meyer M.C., Straughn A.B., Mhatre R.M., Shah V.P., Williams R.L., and Lesko L.J. The relative bioavailability and in vivo-in vitro correlations for four marketed carbamazepine tablets. Pharm Res 15 (1998) 1787-1791
23. Olling M., Mensinga T.T., Barends D.M., Groen C., Lake O.A., and Meulenbelt J. Bioavailability of carbamazepine from four different products and the occurrence of side effects. Biopharm Drug Dispos 20 (1999) 19-28
24. Borgheini G. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clin Ther 25 (2003) 1578-1592
25. Levy G. What are narrow therapeutic index drugs?. Clin Pharmacol Ther 63 (1998) 501-505
26. Goodwin M. The importance of brand continuity in epilepsy drugs. Nurs Times 101 (2005) 26-27
27. Jumao-as A., Bella I., Craig B., Lowe J., and Dasheiff R.M. Comparison of steady-state blood levels of two carbamazepine formulations. Epilepsia 30 (1989) 67-70
28. Oles K.S., Penry J.K., Smith L.D., Anderson R.L., Dean J.C., and Riela A.R. Therapeutic bioequivalency study of brand name versus generic carbamazepine. Neurology 42 (1992) 1147-1153
29. Vadney V.J., and Kraushaar K.W. Effects of switching from Depakene to generic valproic acid on individuals with mental retardation. Ment Retard 35 (1997) 468-472
30. Wolf P., May T., Tiska G., and Schreiber G. Steady state concentrations and diurnal fluctuations of carbamazepine in patients after different slow release formulations. Arzneimittelforschung 42 (1992) 284-288
31. Makus K. Generic substitution of antiepileptic drugs: preliminary observational reports of lamotrigine switching in Canada. Epilepsia 46 (2005) 279
32. Jain K.K. Investigation and management of loss of efficacy of an antiepileptic medication using carbamazepine as an example. J R Soc Med 86 (1993) 133-136
33. Haskins L.S., Tomaszewski K.J., and Crawford P. Patient and physician reactions to generic antiepileptic substitution in the treatment of epilepsy. Epilepsy Behav 7 (2005) 98-105
34. Crawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs 16 (2002) 263-272
35. Tettenborn B. Management of epilepsy in women of childbearing age: practical recommendations. CNS Drugs 20 (2006) 373-387